{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:16:40Z","timestamp":1793744200374,"version":"4.6.1"},"reference-count":236,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Cancer is one of the leading causes of death in the world, which is the second after heart diseases. Adenoviruses (Ads) have become the promise of new therapeutic strategy for cancer treatment. The objective of this review is to discuss current advances in the applications of adenoviral vectors in cancer therapy. Adenoviral vectors can be engineered in different ways so as to change the tumor microenvironment from cold tumor to hot tumor, including; 1. by modifying Ads to deliver transgenes that codes for tumor suppressor gene (p53) and other proteins whose expression result in cell cycle arrest 2. Ads can also be modified to express tumor specific antigens, cytokines, and other immune-modulatory molecules. The other strategy to use Ads in cancer therapy is to use oncolytic adenoviruses, which directly kills tumor cells. Gendicine and Advexin are replication-defective recombinant human p53 adenoviral vectors that have been shown to be effective against several types of cancer. Gendicine was approved for treatment of squamous cell carcinoma of the head and neck by the Chinese Food and Drug Administration (FDA) agency in 2003 as a first-ever gene therapy product. Oncorine and ONYX-015 are oncolytic adenoviral vectors that have been shown to be effective against some types of cancer. The Chiness FDA agency has also approved Oncorin for the treatment of head and neck cancer. Ads that were engineered to express immune-stimulatory cytokines and other immune-modulatory molecules such as TNF-\u03b1, IL-2, BiTE, CD40L, 4-1BBL, GM-CSF, and IFN have shown promising outcome in treatment of cancer. Ads can also improve therapeutic efficacy of immune checkpoint inhibitors and adoptive cell therapy (Chimeric Antigen Receptor T Cells). In addition, different replication-deficient adenoviral vectors (Ad5-CEA, Ad5-PSA, Ad-E6E7, ChAdOx1\u2013MVA and Ad-transduced Dendritic cells) that were tested as anticancer vaccines have been demonstrated to induce strong antitumor immune response. However, the use of adenoviral vectors in gene therapy is limited by several factors such as pre-existing immunity to adenoviral vectors and high immunogenicity of the viruses. Thus, innovative strategies must be continually developed so as to overcome the obstacles of using adenoviral vectors in gene therapy.<\/jats:p>","DOI":"10.3389\/fonc.2022.772659","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T05:33:51Z","timestamp":1654752831000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Role of Adenoviruses in Cancer Therapy"],"prefix":"10.3389","volume":"12","author":[{"given":"Sintayehu Tsegaye","family":"Tseha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr Gene Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2174\/1568009617666170222123925","article-title":"The Development of Oncoltyic Adenovirus Therapy in the Past and Future\u2014For the Case of Pancreatic Cancer","volume":"18","author":"Sato-Dahlman","year":"2018","journal-title":"Curr Cancer Drug Targets"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.24.13407-13411.2003","article-title":"Detailed Analysis of the CD8+ T-Cell Response Following Adenovirus Vaccination","volume":"77","author":"Yang","year":"2003","journal-title":"J Virol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","article-title":"Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine","volume":"4","author":"Lee","year":"2017","journal-title":"Genes Dis"},{"key":"B5","article-title":"Adenoviridae: The Viruses and Their Replication","volume-title":"Virology","author":"Shenk","year":"1996"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1586\/erv.09.29","article-title":"Strategies to Overcome Host Immunity to Adenovirus Vectors in Vaccine Development","volume":"8","author":"Thacker","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/hum.2013.2527","article-title":"Adenovirus: The First Effective In Vivo Gene Delivery Vector","volume":"25","author":"Crystal","year":"2014","journal-title":"Hum Gene Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.13691","article-title":"State-Of-the-Art Human Adenovirus Vectorology for Therapeutic Approaches","volume":"593","author":"Gao","year":"2019","journal-title":"FEBS Lett"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2007.10.010","article-title":"Replicating and non-Replicating Viral Vectors for Vaccine Development","volume":"18","author":"Robert-Guroff","year":"2007","journal-title":"Curr Opin Biotechnol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2174\/1566523013348689","article-title":"Adenoviral Vector-Mediated Gene Transfer for Human Gene Therapy","volume":"2","author":"Breyer","year":"2001","journal-title":"Curr Gene Ther"},{"key":"B11","article-title":"Adenoviridae","volume-title":"Fields Virology","author":"Berk","year":"2013"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01488-15","article-title":"The Intracellular Domain of the Coxsackievirus and Adenovirus Receptor Differentially Influences Adenovirus Entry","volume":"89","author":"Loustalot","year":"2015","journal-title":"J Virol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41467-019-08599-y","article-title":"Diversity Within the Adenovirus Fiber Knob Hypervariable Loops Influences Primary Receptor Interactions","volume":"10","author":"Baker","year":"2019","journal-title":"Nat Commun"},{"key":"B14","article-title":"Targeting of Adenovirus Penton Base to New Receptors Through Replacement of its RGD Motif With Other Receptor-Specific Peptide Motifs","volume":"2","author":"Wickham","year":"1995","journal-title":"Gene Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.70.3.1836-1844.1996","article-title":"Analysis of 15 Adenovirus Hexon Proteins Reveals the Location and Structure of Seven Hypervariable Regions Containing Serotype-Specific Residues","volume":"70","author":"Crawford-Miksza","year":"1996","journal-title":"J Virol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7600653","article-title":"A Quasi-Atomic Model of Human Adenovirus Type 5 Capsid","volume":"24","author":"CMM","year":"2005","journal-title":"EMBO J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2012.04.005","article-title":"Adenovirus Receptors: Implications for Targeting of Viral Vectors","volume":"33","author":"Amberg","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.4.2604-2613.2005","article-title":"Early Steps of Clathrin-Mediated Endocytosis Involved in Phagosomal Escape of Fc\u03b3 Receptor-Targeted Adenovirus","volume":"79","author":"Meier","year":"2005","journal-title":"J Virol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1743-422X-7-148","article-title":"Integrin \u03b1v\u03b25 is a Primary Receptor for Adenovirus in CAR- Negative Cells","volume":"7","author":"Lyle","year":"2010","journal-title":"Virol J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004657","article-title":"Human Adenovirus 52 Uses Sialic Acid-Containing Glycoproteins and the Coxsackie and Adenovirus Receptor for Binding to Target Cells","volume":"11","author":"Lenman","year":"2015","journal-title":"PloS Pathog"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nm952","article-title":"CD46 is a Cellular Receptor for Group B Adeno- Viruses","volume":"9","author":"Gaggar","year":"2003","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2008.38","article-title":"Subversion of CtBP1-Controlled Macropinocytosis by Human Adenovirus Serotype 3","volume":"27","author":"Amstutz","year":"2008","journal-title":"EMBO J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2004.15.1022","article-title":"Biology of Adenovirus and its Use as a Vector for Gene Therapy","volume":"15","author":"McConnell","year":"2004","journal-title":"Hum Gene Ther"},{"key":"B24","article-title":"Adenoviruses","volume-title":"Fields Virology","author":"Wold","year":"2007"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.19497-0","article-title":"Genetic Content and Evolution of Adenoviruses","volume":"84","author":"Davison","year":"2003","journal-title":"J Gen Virol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(62)90018-1","article-title":"Identification and Classification of Adenoviruses","volume":"18","author":"Ginsberg","year":"1962","journal-title":"Virol"},{"key":"B27","article-title":"Adenoviridae: The Adenoviruses","volume-title":"Laboratory Diagnosis of Infectious Diseases Principles and Practice","author":"Wadell","year":"1998"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-662-05597-7_1","article-title":"Virus-Host H. Molecular Evolution of Adenoviruses","volume":"272","author":"Benk\u00f6","year":"2003","journal-title":"Curr Topics Micro- Biol Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/1743-422X-9-287","article-title":"A Serological Survey of Human Adenovirus Serotype 2 and 5 Circulating Pediatric Populations in Changchun, China","volume":"9","author":"Yu","year":"2012","journal-title":"Virol J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/biomedicines6010030","article-title":"The Repertoire of Adenovirus in Human Disease: The Innocuous to the Deadly","volume":"6","author":"Khanal","year":"2018","journal-title":"Biomed"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.753","article-title":"Incidence and Clinical Manifestations of Adenoviral Infection Among Children Undergoing Allogeneic Stem Cell Transplantation","volume":"11","author":"Ephros","year":"2009","journal-title":"IMAJ"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.6.2666-2673.2004","article-title":"Neutralizing Anti- Bodies and CD8+ T Lymphocytes Both Contribute to Immunity to Adenovirus Serotype 5 Vaccine Vectors","volume":"78","author":"Sumida","year":"2004","journal-title":"J Virol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.11.7179","article-title":"Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily Against the Adenovirus Hexon Protein","volume":"174","author":"Sumida","year":"2005","journal-title":"J Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23546","article-title":"Seroprevalence of Neutralizing Anti- Bodies to Human Adenoviruses Type-5 and Type-26 and Chimpanzee Adenovirus Type- 68 in Healthy Chinese Adults","volume":"85","author":"Zhang","year":"2013","journal-title":"J Med Virol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4161\/hv.29594","article-title":"Pre-Existing Immunity Against Ad Vectors: Humoral, Cellular, and Innate Response, What\u2019s Important","volume":"10","author":"Fausther-Bovendo","year":"2014","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002925","article-title":"Vaccine Vectors Derived From a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species","volume":"4","author":"Colloca","year":"2012","journal-title":"Sci Trans Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1383575","article-title":"Chimpanzee Adenoviral Vectors as Vaccines for Outbreak Pathogens","volume":"13","author":"Ewer","year":"2017","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00159-18","article-title":"Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors","volume":"92","author":"Iampietro","year":"2018","journal-title":"J Virol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.13.093195","article-title":"ChAdOx1 Ncov-19 Vaccination Prevents SARS-CoV-2 Pneumonia in Rhesus Macaques","author":"Doremalen","year":"2020","journal-title":"bioRxiv preprint"},{"key":"B40","doi-asserted-by":"publisher","first-page":"6(7)","DOI":"10.1172\/jci.insight.141912","article-title":"Characterization of Recombinant Gorilla Adenovirus HPV Therapeutic Vaccine PRGN-2009","volume":"8","author":"Pellom","year":"2021","journal-title":"JCI Insight"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.19.8802","article-title":"An Efficient and Flexible System for Construction of Adenovirus Vectors With Insertions or Deletions in Early Regions 1 and 3","volume":"91","author":"Bett","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(99)80064-8","article-title":"Immune Responses to Adenoviruses: Viral Evasion Mechanisms and Their Implications for the Clinic","volume":"11","author":"Wold","year":"1999","journal-title":"Curr Opin Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.3.2022-2032.1998","article-title":"In Vitro and In Vivo Biology of Recombinant Adenovirus Vectors With E1, E1\/E2A, or E1\/E4 Deleted","volume":"72","author":"Lusky","year":"1998","journal-title":"J Virol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2741\/1607","article-title":"Adenovirus Vectors Deleted for Genes Essential for Viral DNA Replication","volume":"1","author":"Schaack","year":"2005","journal-title":"Front Biosci: A J Virtual Library"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/nm0696-714","article-title":"Second-Generation Adenovirus Vectors","volume":"2","author":"Wang","year":"1996","journal-title":"Nat Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.12.5731","article-title":"A New Adenoviral Vector: Replacement of All Viral Coding Sequences With 28 Kb of DNA Independently Expressing Both Full-Length Dystrophin and Beta-Galactosidase","volume":"93","author":"Kochanek","year":"1996","journal-title":"Proc Natl Acad Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00398-10","article-title":"A Novel Bicistronic High-Capacity Gutless Adenovirus Vector That Drives Constitutive Expression of Herpes Simplex Virus Type 1 Thymidine Kinase and Tet-Inducible Expression of Flt3L for Glioma Therapeutics","volume":"84","author":"Puntel","year":"2010","journal-title":"J Virol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.2174\/156652312800840603","article-title":"Gene Therapy for Duchenne Muscular Dystrophy by the Helper-Dependent Adenovirus Vector (HDAdv)\u2014Mediated Full-Length Dystrophin Expression","volume":"15","author":"Ishizaki","year":"2018","journal-title":"Mol Ther"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.24.13565","article-title":"A Helper-Dependent Adenovirus Vector System: Removal of Helper Virus by Cre-Mediated Excision of the Viral Packaging Signal","volume":"93","author":"Parks","year":"1996","journal-title":"PNAS"},{"key":"B50","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1006\/viro.1996.0088","article-title":"Recombinant Adenovirus Deleted of All Viral Genes for Gene Therapy of Cystic Fibrosis","volume":"217","author":"Fisher","year":"1996","journal-title":"Virol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.71.3.1842-1849.1997","article-title":"Construction of Adenovirus Vectors Through Cre-Lox Recombination","volume":"71","author":"Hardy","year":"1997","journal-title":"J Virol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/ng0298-180","article-title":"Genomic DNA Transfer With a High-Capacity Adenovirus Vector Results in Improved In Vivo Gene Expression and Decreased Toxicity","volume":"18","author":"Schiedner","year":"1998","journal-title":"Nat Genet"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1998.9.18-2709","article-title":"High Doses of a Helper-Dependent Adenoviral Vector Yield Supraphysiological Levels of Alpha1- Antitrypsin With Negligible Toxicity","volume":"81","author":"Morral","year":"1999","journal-title":"Hum Gene Ther"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2003.08.014","article-title":"Improved System for Helper-Dependent Adenoviral Vector Production. Molecular Therapy","volume":"8","author":"Palmer","year":"2003","journal-title":"J Am Soc Gene Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.1509","article-title":"Immunology and Immunotherapy of Head and Neck Cancer","volume":"33","author":"Ferris","year":"2015","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ctrv.2018.03.003","article-title":"Immuno-Oncology in Head and Neck Squamous Cell Cancers: News From Clinical Trials, Emerging Predictive Factors and Unmet Needs","volume":"65","author":"Cavalieri","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B58","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to Treat Immune Hot, Altered and Cold Tumours With Combination Immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1507","article-title":"The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Check-Point Inhibition","volume":"22","author":"Hegde","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501","article-title":"TGFb Atten-Uates Tumour Response to PD-L1 Blockade by Contributing to Exclusion of T Cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011","article-title":"Predictive Correlates of Response to the Anti-PD-L1 Antibody MPDL3280A in Cancer Patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190","article-title":"IFN-G-Related mRNA Profile Predicts Clinical Response to PD-1 Blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06705.x","article-title":"Immunodeficiency and Immunotherapy in Multiple Myeloma","volume":"138","author":"Pratt","year":"2007","journal-title":"Br J Haematol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"198539","DOI":"10.1155\/2014\/198539","article-title":"Immunological Dysregulation in Multiple Myeloma Microenvironment","volume":"2014","author":"Romano","year":"2014","journal-title":"BioMed Res Int"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98368","article-title":"Efficacy of Intracellular Immune Checkpoint-Silenced DC Vaccine","volume":"3","author":"Wang","year":"2018","journal-title":"JCI Insight"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/hed.24406","article-title":"Tumor Infiltrating Lymphocytes and Survival in Patients With Head and Neck Squamous Cell Carcinoma","volume":"38","author":"Nguyen","year":"2016","journal-title":"Head Neck"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2017.12.003","article-title":"Proportion of CD4 and CD8 Tumor Infiltrating Lymphocytes Predicts Survival in Persistent\/Recurrent Laryngeal Squamous Cell Carcinoma","volume":"77","author":"Hoesli","year":"2018","journal-title":"Oral Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2019.2427","article-title":"Prognostic Value of Tumor-Infiltrating Lymphocytes in Head and Neck Squamous Cell Carcinoma","volume":"45","author":"Spector","year":"2019","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02479-x","article-title":"The Repertoire of Tumor-Infiltrating Lymphocytes Within the Microenvironment of Oral Squamous Cell Carcinoma Reveals Immune Dysfunction","volume":"69","author":"Quan","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1747345","DOI":"10.1080\/2162402X.2020.1747345","article-title":"The Prognostic Role of NK Cells and Their Ligands in Squamous Cell Carcinoma of the Head and Neck: A Systematic Review and Meta-Analysis","volume":"9","author":"Bisheshar","year":"2020","journal-title":"Oncoimmunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.4.5.1705","article-title":"Vector-Mediated Cancer Gene Therapy: An Overview","volume":"4","author":"Seth","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1177\/153303460500400402","article-title":"Cancer Gene Therapy","volume":"4","author":"Curiel","year":"2005","journal-title":"Technol Cancer Res Treat"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14126","article-title":"Tumor Suppressor BLU Promotes TRAIL-Induced Apoptosis by Downregulating NF-\u03bab Signaling in Nasopharyngeal Carcinoma","volume":"8","author":"Zhou","year":"2014","journal-title":"Oncotarget"},{"key":"B75","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coviro.2016.06.009","article-title":"Recent Advances in Oncolytic Adenovirus Therapies for Cancer","volume":"21","author":"Shaw","year":"2016","journal-title":"Curr Opin Virol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2017.21","article-title":"Combination of P53-DC Vaccine and rAd-P53 Gene Therapy Induced CTLs Cytotoxic Against P53-Deleted Human Prostate Cancer Cells In Vitro","volume":"24","author":"Saito","year":"2017","journal-title":"Cancer Gene Ther"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2763","article-title":"Awakening Guardian Angels: Drugging the P53 Pathway","volume":"9","author":"Brown","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B78","article-title":"Accumulation of P53 Protein Correlates With a Poor Prognosis in Human Lung Cancer","volume":"52","author":"Quinlan","year":"1992","journal-title":"Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1994.tb02936.x","article-title":"Prognostic Significance of P53 and Ras Gene Abnormalities in Lung Adenocarcinoma Patients With Stage I Disease After Curative Resection","volume":"85","author":"Isobe","year":"1994","journal-title":"Jpn J Cancer Res"},{"key":"B80","article-title":"Recombinant Adenovirus P53 Agent Injection Combined With Radiotherapy in Treatment of Nasopharyngeal Carcinoma: A Phase II Clinical Trial","volume":"83","author":"Chen","year":"2003","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B81","article-title":"Treatment of Head and Neck Squamous Cell Carcinoma by Recombinant Adenovirus-P53 Combined With Radiotherapy: A Phase II Clinical Trial of 42 Cases","volume":"83","author":"Zhang","year":"2003","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B82","article-title":"Recombinant Adenovirus-P53 Gene Therapy Combined With Radiotherapy for Head and Neck Squamous-Cell Carcinoma","volume":"27","author":"Zhang","year":"2005","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B83","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.ymthe.2006.08.061","article-title":"A Combination Therapy of Selective Intraarterial Gendicine Infusion With Chemotherapy for Locally Advanced Head and Neck Carcinoma","volume":"13","author":"Li","year":"2006","journal-title":"Mol Ther"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000448","article-title":"Efficacy and Safety of Recombinant Human Adenovirus P53 Combined With Chemoradiotherapy in the Treatment of Recurrent Nasopharyngeal Carcinoma","volume":"28","author":"Ma","year":"2012","journal-title":"Anticancer Drugs"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-016-3574-6","article-title":"Recombinant Adenovirus P53 Agent Injection Combined With Radiotherapy and Chemotherapy for Intermediate and Advanced Stage Nasopharyngeal Carcinoma","volume":"36","author":"Si","year":"2009","journal-title":"Chin J Clin Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-016-3574-6","article-title":"Clinical Observations of Recombinant Adenovirus-P53 Combined With Radiotherapy on Nasopharyngeal Squamous Carcinoma","volume":"21","author":"Wang","year":"2012","journal-title":"Mod J Int Tradit Chin West Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2013.30","article-title":"Randomized, Controlled Phase II Study of Post-Surgery Radiotherapy Combined With Recombinant Adenoviral Human P53 Gene Therapy in Treatment of Oral Cancer","volume":"20","author":"Liu","year":"2013","journal-title":"Cancer Gene Ther"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2016.043","article-title":"Effect and Safety of Recombinant Adenovirus-P53 Transfer Combined With Radiotherapy on Long-Term Survival of Locally Advanced Cervical Cancer","volume":"27","author":"Su","year":"2016","journal-title":"Hum Gene Ther"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.206","article-title":"Treatment of Uterine Sarcoma With rAd-P53 (Gendicine) Followed by Chemotherapy: Clinical Study of TP53 Gene Therapy","volume":"29","author":"Xia","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S50483","article-title":"Clinical Utility of Recombinant Ade- Noviral Human P53 Gene Therapy: Current Perspectives","volume":"7","author":"Chen","year":"2014","journal-title":"Onco Targets Ther"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.218","article-title":"The First Approved Gene Therapy Product for Cancer Ad-P53 (Gendicine): 12 Years in the Clinic","volume":"29","author":"Zhang","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.6.8.823","article-title":"INGN 201 (Advexin): Adenoviral P53 Gene Therapy for Cancer","volume":"6","author":"Gabrilovich","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"B93","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2174\/1874467210801010013","article-title":"Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms, and Clinical Indications","volume":"1","author":"R\u00e4ty","year":"2008","journal-title":"Curr Mol Pharmacol"},{"key":"B94","first-page":"54","article-title":"A Review of Contusugene Ladenovec (Advexin) P53 Therapy","volume":"11","author":"Senzer","year":"2009","journal-title":"Curr Opin Mol Ther"},{"key":"B95","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1001\/archoto.2009.122","article-title":"A Phase 2 Trial of Surgery With Perioperative INGN 201 (Ad5CMV-P53) Gene Therapy Followed by Chemoradiotherapy for Advanced, Resectable Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Hypopharynx, and Larynx: Report of the Southwest Oncology Group","volume":"135","author":"Yoo","year":"2009","journal-title":"Arch Otolaryngol Neck Surg"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2998","article-title":"Classification of Current Anticancer Immunotherapies","volume":"5","author":"Galluzzi","year":"2014","journal-title":"Oncotarget"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0244","article-title":"Eliminating Established Tumor in Nu\/Nu Nude Mice by a Tumor Necrosis Factor-A-Related Apoptosis-Inducing Ligand Armed Oncolytic Adenovirus","volume":"12","author":"Dong","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.2174\/156800907780058817","article-title":"Clinical Trials With Oncolytic Adenovirus in China","volume":"7","author":"Yu","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700840","article-title":"Inefficient Killing of Quiescent Human Epithelial Cells by Replicating Adenoviruses: Potential Implications for Their Use as Oncolytic Agents","volume":"12","author":"Vaillancourt","year":"2005","journal-title":"Cancer Gene Ther"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1126\/science.1155546","article-title":"Epigenetic Reprogramming by Adenovirus E1a","volume":"321","author":"Ferrari","year":"2008","journal-title":"Sci"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1126\/science.282.5392.1332","article-title":"Reovirus Therapy of Tumors With Activated Ras Pathway","volume":"282","author":"Coffey","year":"1998","journal-title":"Sci"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.53","article-title":"Oncolytic Herpes Virus With Defective ICP6 Specifically Replicates in Quiescent Cells With Homozygous Genetic Mutations in P16","volume":"27","author":"Aghi","year":"2008","journal-title":"Oncogene"},{"key":"B103","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1476-4598-12-103","article-title":"Oncolytic Viruses as Therapeutic Cancer Vaccines","volume":"12","author":"Bartlett","year":"2013","journal-title":"Mol Cancer"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00866","article-title":"Oncolytic Viral Ther-Apy and the Immune System: A Double-Edged Sword Against Cancer","volume":"9","author":"Marelli","year":"2018","journal-title":"Front Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5286.373","article-title":"An Adenovirus Mutant That Replicates Selectively in P53-Deficient Human Tumor Cells","volume":"274","author":"Bischoff","year":"1996","journal-title":"Science"},{"key":"B107","article-title":"Intravenous Administration of ONYX- 015, a Selectively Replicating Adenovirus, Induces Antitumoral Efficacy","volume":"59","author":"Heise","year":"1999","journal-title":"Cancer Res"},{"key":"B108","doi-asserted-by":"publisher","first-page":"nm0800_879.7","DOI":"10.1038\/78638","article-title":"A Controlled Trial of Intratumoral ONYX-015, a Selectively-Replicating Adenovirus, in Combination With Cisplatin and 5-Fluorouracil in Patients With Recurrent Head and Neck Cancer","volume":"6","author":"Khuri","year":"2000","journal-title":"Nat Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.230","article-title":"Development of Gene Therapeutics for Head and Neck Cancer in China: From Bench to Bedside","volume":"29","author":"Guo","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.4161\/onci.20172","article-title":"Oncolytic Adenoviruses","volume":"1","author":"Cerullo","year":"2012","journal-title":"Onco Immunol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13228","article-title":"Recent Advances in Genetic Modification of Adenovirus Vectors for Cancer Treatment","volume":"108","author":"Yamamoto","year":"2017","journal-title":"Cancer Sci"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.2174\/1568009617666170502152352","article-title":"Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System","volume":"8","author":"Cerullo","year":"2018","journal-title":"Curr Cancer Drug Targets"},{"key":"B113","doi-asserted-by":"crossref","first-page":"794","DOI":"10.4049\/jimmunol.159.2.794","article-title":"Interferons Up-Regulate STAT1, STAT2, and IRF Family Transcription Factor Gene Expression in Human Peripheral Blood Mononuclear Cells and Macrophages","volume":"159","author":"Lehtonen","year":"1997","journal-title":"J Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9610(00)00369-X","article-title":"Interferon-Based Adjuvant Chemoradiation Therapy Improves Survival After Pancreaticoduodenectomy for Pancreatic Adenocarcinoma","volume":"179","author":"Nukui","year":"2000","journal-title":"Am J Surg"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9610(03)00051-5","article-title":"Interferon-Based Adjuvant Chemoradiation Therapy After Pancreaticoduodenectomy for Pancreatic Adenocarcinoma","volume":"185","author":"Picozzi","year":"2003","journal-title":"Am J Surg"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1111\/hpb.12086","article-title":"Neoadjuvant Interferon-Based Chemoradiation for Borderline Resectable and Locally Advanced Pancreas Cancer: A Phase II Pilot Study","volume":"16","author":"Jensen","year":"2014","journal-title":"HPB"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00262-004-0549-1","article-title":"New Pharmacokinetic and Pharmacodynamic Tools for Interferon-Alpha (IFN-\u03b1) Treatment of Human Cancer","volume":"54","author":"Tagliaferri","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.110973","article-title":"Pegylated Interferon-\u03b12b: Pharmacokinetics, Pharmacodynamics, Safety, and Preliminary Efficacy Data","volume":"68","author":"Glue","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2012.02.016","article-title":"Generation of a Novel, Cyclooxygenase-2-Targeted, Interferon-Expressing, Conditionally Replicative Adenovirus for Pancreatic Cancer Therapy","volume":"204","author":"Armstrong","year":"2012","journal-title":"Am J Surg"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2012.02.017","article-title":"Delivery of Interferon Alpha Using a Novel Cox2-Controlled Adenovirus for Pancreatic Cancer Therapy","volume":"152","author":"Armstrong","year":"2012","journal-title":"Surg"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1996.0295","article-title":"The E3-11.6-kDa Adenovirus Death Protein (ADP) is Required for Efficient Cell Death:Characterization of Cells Infected With Adp Mutants","volume":"220","author":"Tollefson","year":"1996","journal-title":"Virol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2015.01.006","article-title":"Oncolytic Adenovirus Expressing Interferon Alpha in a Syngeneic Syrian Hamster Model for the Treatment of Pancreatic Cancer","volume":"157","author":"LaRocca","year":"2015","journal-title":"Surg"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24710","article-title":"Combination of Interferon-Expressing Oncolytic Adenovirus With Chemotherapy and Radiation is Highly Synergistic in Hamster Model of Pancreatic Cancer","volume":"9","author":"Salzwedel","year":"2018","journal-title":"Oncotarget"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700865","article-title":"Efficacy of a Single Intravesical Treatment With Ad-IFN\/Syn 3 is Dependent on Dose and Urine IFN Concentration Obtained: Implications for Clinical Investigation","volume":"13","author":"Tao","year":"2006","journal-title":"Cancer Gene Ther"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3390\/cancers3043856","article-title":"Cytokines in Cancer Immunotherapy","volume":"3","author":"Lee","year":"2011","journal-title":"Cancers (Basel)"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0438","article-title":"Intratumoral Immunotherapy\u2014Update 2019","volume":"25","author":"Hamid","year":"2020","journal-title":"Oncologist"},{"key":"B127","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I Study With ONCOS-102 for the Treatment of Solid Tumors - an Evaluation of Clinical Response and Exploratory Analyses of Immune Markers","volume":"4","author":"Ranki","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0285","article-title":"Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus","volume":"23","author":"Eriksson","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131242","article-title":"Favorable Alteration of Tumor Microenvironment by Immunomodulatory Cytokines for Efficient T-Cell Therapy in Solid Tumors","volume":"10","author":"T\u00e4htinen","year":"2015","journal-title":"PloS One"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.137","article-title":"Adenoviral Delivery of Tumor Necrosis Factor-\u03b1 and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma","volume":"24","author":"Siurala","year":"2016","journal-title":"Mol Ther"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6101(01)00032-6","article-title":"Interleukin-12 in Anti-Tumor Immunity and Immunotherapy","volume":"13","author":"Colombo","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0776","article-title":"Interleukin-12: Biological Properties and Clinical Application","volume":"13","author":"Del Vecchio","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1084\/jem.178.4.1223","article-title":"Antitumor and Antimetastatic Activity of Interleukin 12 Against Murine Tumors","volume":"178","author":"Brunda","year":"1993","journal-title":"J Exp Med"},{"key":"B134","article-title":"Optimal Scheduling of Interleukin 12 and Chemotherapy in the Murine MB-49 Bladder Carcinoma and B16 Melanoma","volume":"3","author":"Teicher","year":"1997","journal-title":"Clin Cancer Res"},{"key":"B135","article-title":"Interleukin 12-Based Immunotherapy Improves the Antitumor Effectiveness of a Low-Dose 5-Aza-2\u2032-Deoxycitidine Treatment in L1210 Leukemia and B16F10 Melanoma Models in Mice","volume":"9","author":"Kozar","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1021\/mp300602j","article-title":"Enhanced Antitumor Response Mediated by the Codelivery of Paclitaxel and Adenoviral Vector Expressing IL-12","volume":"10","author":"Cao","year":"2013","journal-title":"Mol Pharm"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.575597","article-title":"Localized Interleukin-12 for Cancer Immunotherapy","volume":"11","author":"Nguyen","year":"2020","journal-title":"Front Immunol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1523-1","article-title":"Interleukin 12: Still a Promising Candidate for Tumor Immunotherapy","volume":"63","author":"Lasek","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.059","article-title":"Phase I Trial of Intratumoral Injectio of an Adenovirus Encoding Interleukin-12 for Advanced Digestive Tumors","volume":"22","author":"Sangro","year":"2004","journal-title":"J Clin Oncol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.9","article-title":"Treatment of Pancreatic Cancer With an Oncolytic Adenovirus Expressing Interleukin-12 in Syrian Hamsters","volume":"17","author":"Bortolanza","year":"2009","journal-title":"Mol Ther"},{"key":"B141","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/s41467-017-01385-8","article-title":"Re-Designing Interleukin-12 to Enhance its Safety and Potential as an Anti-Tumor Immunotherapeutic Agent","volume":"8","author":"Wang","year":"2017","journal-title":"Nat Commun"},{"key":"B142","doi-asserted-by":"publisher","first-page":"5680","DOI":"10.1126\/scitranslmed.aaw5680","article-title":"Regulatable Interleukin-12 Gene Therapy in Patients With Recurrent High-Grade Glioma: Results of a Phase 1 Trial","volume":"11","author":"Chiocca","year":"2019","journal-title":"Sci Transl Med"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.06.001","article-title":"Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy","volume":"26","author":"Santos","year":"2018","journal-title":"Mol Ther"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015875","article-title":"Interleukin-24 Enhancing Antitumor Activity of Chimeric Oncolytic Adenovirus for Treating Acute Promyelocytic Leukemia Cell","volume":"98","author":"Liu","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S203638","article-title":"Efficacy of a New Oncolytic Adenovirus Armed With IL-13 Against Oral Carcinoma Models","volume":"12","author":"Zhang","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318193d31e","article-title":"Targeting the Intratumoral Dendritic Cells by the Oncolytic Adenoviral Vaccine Expressing RANTES Elicits Potent Antitumor Immunity","volume":"32","author":"Lapteva","year":"2009","journal-title":"J Immunother"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T Cell Engager for Cancer Immunotherapy","volume":"93","author":"Huehls","year":"2014","journal-title":"Immunol Cell Biol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2005.07.034","article-title":"MT110: A Novel Bispecfic Single Chain Antibody Construct With High Efficacy in Eradicating Established Tumors","volume":"43","author":"Brischwein","year":"2006","journal-title":"Mol Immunol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158545","article-title":"Tumor Regression in Cancer Patients by Very Low Doses of a T-Cell Engaging Antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Sci"},{"key":"B150","doi-asserted-by":"publisher","first-page":"XI18","DOI":"10.1093\/annonc\/mdx711.042","article-title":"Arming Oncolytic Adenovirus With FAP-Targeting Bispecific T-Cell Engager to Improve Antitumor Efficacy","author":"Pom\u00e9s","year":"2017","journal-title":"Ann Oncol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-1708","article-title":"Oncolytic Adenoviral Delivery of an Egfr-Targeting T-Cell Engager Improves Antitumor Efficacy","volume":"77","author":"Fajardo","year":"2017","journal-title":"Cancer Res"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0314","article-title":"Improving CART-Cell Therapy of Solid Tumors With Oncolytic Virus-Driven Production of a Bispecific T-Cell Engager","volume":"6","author":"Wing","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201707567","article-title":"Oncolytic Adenovirus Expressing Bispecific Antibody Targets T-Cell Cytotoxicity in Cancer Biopsies","volume":"9","author":"Freedman","year":"2017","journal-title":"EMBO Mol Med"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1750","article-title":"An Oncolytic Virus Expressing a T-Cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells","volume":"78","author":"Freedman","year":"2018","journal-title":"Cancer Res"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1679-3","article-title":"Gene-Mediated Cytotoxic Immunotherapy as Adjuvant to Surgery or Chemoradiation for Pancreatic Adenocarcinoma","volume":"64","author":"Aguilar","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1089\/10430349950018229","article-title":"In Situ Gene Therapy for Adenocarcinoma of the Prostate: A Phase I Clinical Trial","volume":"10","author":"Herman","year":"1999","journal-title":"Hum Gene Ther"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.1883","article-title":"Response of Retinoblastoma With Vitreous Tumor Seeding to Adenovirus-Mediated Delivery of Thymidine Kinase Followed by Ganciclovir","volume":"23","author":"Ch\u00e9vez-Barrios","year":"2005","journal-title":"J Clin Oncol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0405","article-title":"Long-Term Follow-Up of Patients With Malignant Pleural Mesothelioma Receiving High-Dose Adenovirus Herpes Simplex Thymidine Kinase\/Ganciclovir Suicide Gene Therapy","volume":"11","author":"Sterman","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.2174\/156652309789753365","article-title":"Adenovirus Mediated Herpes Simplex Virus-Thymidine Kinase\/Ganciclovir Gene Therapy for Resectable Malignant Glioma","volume":"9","author":"Maatta","year":"2009","journal-title":"Curr Gene Ther"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-042718-041407","article-title":"Emerging Cellular Therapies for Cancer","volume":"37","author":"Guedan","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-019-0070-9","article-title":"Genetically Engineered T Cells for Cancer Immunotherapy","volume":"4","author":"Li","year":"2019","journal-title":"Signal Transduction Targeting Ther"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-Lineage Cells and Regression of Lymphoma in a Patient Treated With Autologous T Cells Genetically Engineered to Recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"B164","doi-asserted-by":"publisher","first-page":"16006","DOI":"10.1038\/mto.2016.6","article-title":"Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors","volume":"3","author":"Newick","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99573","article-title":"Pancreatic Cancer Therapy With Combined Mesothelin-Redirected Chimeric Antigen Receptor T Cells and Cytokine-Armed Oncolytic Adenoviruses","volume":"3","author":"Watanabe","year":"2018","journal-title":"JCI Insight"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-1577","article-title":"Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors","volume":"77","author":"Tanoue","year":"2017","journal-title":"Cancer Res"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0697","article-title":"Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor-Modified T Cells in Solid Tumors","volume":"74","author":"Nishio","year":"2014","journal-title":"Cancer Res"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.09.010","article-title":"Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells Against Metastatic Head and Neck Cancer","volume":"25","author":"Rosewell","year":"2017","journal-title":"Mol Ther"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.11.028","article-title":"Of Mice and Men: Values and Liabilities of the Athymic Nude Mouse Model in Anticancer Drug Development","volume":"40","author":"Kelland","year":"2004","journal-title":"Eur J Cancer"},{"key":"B170","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.semcdb.2014.04.003","article-title":"Cancer Mouse Models: Past, Present and Future","volume":"27","author":"Khaled","year":"2014","journal-title":"Semin Cell Dev Biol"},{"key":"B171","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/nyas.12180","article-title":"Development of Ipilimumab: A Novel Immunotherapeutic Approach for the Treatment of Advanced Melanoma","volume":"1291","author":"Wolchok","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-7-873","article-title":"Tremelimumab (CP-675,206),a Cytotoxic T Lymphocyte\u2013Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients With Cancer","volume":"12","author":"Ribas","year":"2007","journal-title":"Oncologist"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival With Ipilimumab in Patients With Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2033","article-title":"Phase II Trial of Tremelimumab (CP-675,206) in Patients With Advanced Refractory or Relapsed Melanoma","volume":"16","author":"Kirkwood","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2011.176","article-title":"Targeted Cancer Immunotherapy With Oncolytic Adenovirus Coding for a Fully Human Monoclonal Antibody Specific for CTLA-4","volume":"19","author":"Dias","year":"2012","journal-title":"Gene Ther"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1412902","article-title":"TNFa and IL-2 Armed Adenoviruses Enable Complete Responses by Anti-PD-1 Checkpoint Blockade","volume":"7","author":"Cervera-Carrascon","year":"2018","journal-title":"Oncoimmunology"},{"key":"B177","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A Mutant Oncolytic Adenovirus Targeting the Rb Pathway Produces Anti-Glioma Effect In Vivo","volume":"19","author":"Fueyo","year":"2000","journal-title":"Oncogene"},{"key":"B178","doi-asserted-by":"publisher","first-page":"vi8","DOI":"10.1093\/neuonc\/noz175.032","article-title":"Atim-33. Interim Results of a Phase Ii Multi-Center Study of Oncolytic Adenovirus Dnx-2401 With Pembrolizumab for Recurrent Glioblastoma; Captive Study (Keynote-192)","volume":"21","author":"Aiken","year":"2019","journal-title":"Neuro-Oncology"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.49","article-title":"Immunotherapy: Hiding in Plain Sight: Immune Escape in the Era of Targeted T-Cell-Based Immunotherapies","volume":"14","author":"Daniyan","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00262-018-2131-2","article-title":"Defective HLA Class I Antigen Processing Machinery in Cancer","volume":"67","author":"Cai","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B181","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1046\/j.1365-2249.1999.00857.x","article-title":"Bladder Cancer Immunogenicity: Expression of CD80 and CD86 is Insufficient to Allow Primary CD4+ T Cell Activation In Vitro","volume":"116","author":"Pettit","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-1681","article-title":"Low Surface Expression of B7-1 (CD80) is an Immunoescape Mechanism of Colon Carcinoma","volume":"66","author":"Tirapu","year":"2006","journal-title":"Cancer Res"},{"key":"B183","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/jco.2014.32.15_suppl.3093","article-title":"Immunotherapeutic Treatment of Metastatic Colorectal Cancer Using ETBX-011","volume":"32","author":"Gabitzsch","year":"2014","journal-title":"J Clin Oncol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1400-3","article-title":"Novel Adenoviral Vector Induces T-Cell Responses Despite Anti-Adenoviral Neutralizing Antibodies in Colorectal Cancer Patients","volume":"62","author":"Morse","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1706-4","article-title":"Extended Evaluation of a Phase 1\/2 Trial on Dosing, Safety, Immunogenicity, and Overall Survival After Immunizations With an Advanced-Generation Ad5 [E1-, E2b-]-CEA(6D) Vaccine in Late-Stage Colorectal Cancer","volume":"64","author":"Balint","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5181","article-title":"The Generation and Analyses of a Novel Combination of Recombinant Adenovirus Vaccines Targeting Three Tumor Antigens as an Immunotherapeutic","volume":"6","author":"Gabitzsch","year":"2015","journal-title":"Oncotarget"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0608","article-title":"A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA\/MUC1\/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients With Advanced Cancer","volume":"25","author":"Gatti-Mays","year":"2019","journal-title":"Oncologist"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1556","article-title":"Immunization With Type 5 Adenovirus Recombinant for a Tumor Antigen in Combination With Recombinant Canarypox Virus (Alvac) Cytokine Gene Delivery Induces Destruction of Established Prostate Tumors","volume":"94","author":"Elzey","year":"2001","journal-title":"Int J Cancer"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2006.17.220","article-title":"Clinical Protocol: Phase I Study of an Adenovirus\/Prostate-Specific Antigen Vaccine in Men With Metastatic Prostate Cancer","volume":"17","author":"Lubaroff","year":"2006","journal-title":"Hum Gene Ther"},{"key":"B190","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.3390\/cancers12051295;191","article-title":"An Ongoing Phase II Trial of an Adenovirus\/PSA Vaccine for Prostate Cancer","volume":"72","author":"Lubaroff","year":"2012","journal-title":"Cancer Res"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.111","article-title":"Therapeutic Vaccines for Cancer: An Overview of Clinical Trials. Nat. Rev","volume":"11","author":"Melero","year":"2014","journal-title":"Clin Oncol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2012.55","article-title":"A non-Oncogenic HPV 16 E6\/E7 Vaccine Enhances Treatment of HPV Expressing Tumors","volume":"19","author":"Wieking","year":"2012","journal-title":"Cancer Gene Ther"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.02.070","article-title":"Preclinical Development of Peptide Vaccination Combined With Oncolytic MG1-E6E7 for HPV- Associated Cancer","volume":"36","author":"Atherton","year":"2018","journal-title":"Vaccine"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.2147\/OV.S154494","article-title":"Development and Applications of Oncolytic Maraba Virus Vaccines","volume":"7","author":"Pol","year":"2018","journal-title":"Oncolytic Virother"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1831-8","article-title":"Immunogenicity and Efficacy of the Novel Cancer Vaccine Based on Simian Adenovirus and MVA Vectors Alone and in Combination With PD-1 MAb in a Mouse Model of Prostate Cancer","volume":"65","author":"Cappuccini","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.14.4.771","article-title":"Murine Dendritic Cells Transduced With an Adenoviral Vector Expressing a Defined Tumor Antigen can Overcome Anti-Adenovirus Neutralizing Immunity and Induce Effective Tumor Regression","volume":"14","author":"Wan","year":"1999","journal-title":"Int J Oncol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301670","article-title":"An Effective Immunization and Cancer Treatment With Activated Dendritic Cells Transduced With Full-Length Wild-Type P53","volume":"9","author":"Nikitina","year":"2002","journal-title":"Gene Ther"},{"key":"B198","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.158.7.3270","article-title":"Virus-Mediated Delivery of Antigenic Epitopes Into Dendritic Cells as a Means to Induce CTL","volume":"158","author":"Brossart","year":"1997","journal-title":"J Immunol"},{"key":"B199","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/CJI.0b013e31816a8910","article-title":"Adenovirus MART-1\u2013Engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma","volume":"31","author":"Butterfield","year":"2008","journal-title":"J Immunother"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700472","article-title":"A Phase I\/II Trial of RAd\/P53 (SCH 58500) Gene Replacement in Recurrent Ovarian Cancer","volume":"9","author":"Buller","year":"2002","journal-title":"Cancer Gene Ther"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy202","article-title":"Phase I Study of Gene-Mediated Cytotoxic Immunotherapy With AdV-Tk as Adjuvant to Surgery and Radiation for Pediatric Malignant Glioma and Recurrent Ependymoma","volume":"21","author":"Kieran","year":"2019","journal-title":"Neuro Oncol"},{"key":"B202","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.omto.2016.12.004","article-title":"Oncolytic Adenoviruses Armed With Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy","volume":"4","author":"Havunen","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1002\/hed.25627","article-title":"Intratumoral Generation of 2-Fluoroadenine to Treat Solid Malignancies of the Head and Neck","volume":"41","author":"Behbahani","year":"2019","journal-title":"Head Neck"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.2019","article-title":"First-In-Human Phase I Trial of the Combination of Two Adenoviral Vectors Expressing HSV1-TK and FLT3L for the Treatment of Newly Diagnosed Resectable Malignant Glioma: Initial Results From the Therapeutic Reprogramming of the Brain Immune System","volume":"37","author":"Lowenstein","year":"2019","journal-title":"J Clin Oncol"},{"key":"B205","doi-asserted-by":"publisher","first-page":"S746","DOI":"10.1016\/j.jtho.2018.08.1266","article-title":"P2.06-11 A Phase I\/II Study of Intrapleural Ad-SGE-REIC Administration in Patients With Refractory Malignant Pleural Mesothelioma","volume":"13","author":"Goto","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.114","article-title":"Double-Dose Adenovirus-Mediated Adjuvant Gene Therapy Improves Liver Transplantation Outcomes in Patients With Advanced Hepatocellular Carcinoma","volume":"29","author":"Zhu","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.15.8263-8271.2003","article-title":"Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity","volume":"77","author":"Vogels","year":"2003","journal-title":"J Virol"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.11.2.351-357.2004","article-title":"Prevalence of Neutralizing Antibodies to Adenoviral Serotypes 5 and 35 in the Adult Populations of The Gambia, South Africa, and the United States","volume":"11","author":"Nwanegbo","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0146404","article-title":"Heterologous Immunity Between Adenoviruses and Hepatitis C Virus: A New Paradigm in HCV Immunity and Vaccines","volume":"11","author":"Singh","year":"2016","journal-title":"PloS One"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18081626","article-title":"Unsolved Puzzles Surrounding HCV Immunity: Heterologous Immunity Adds Another Dimension","volume":"18","author":"Agrawal","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.55.091902.104344","article-title":"Recent Advances in the Development of HIV-1 Vaccines Using Replication-Incompetent Adenovirus Vectors. Annu","volume":"55","author":"Shiver","year":"2004","journal-title":"Rev Med"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02667-05","article-title":"Epitopes Expressed in Different Adenovirus Capsid Proteins Induce Different Levels of Epitope-Specific Immunity","volume":"80","author":"Krause","year":"2006","journal-title":"J Virol"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06165-11","article-title":"Adenovirus Serotype 5-Specific Neutralizing Antibodies Target Multiple Hexon Hypervariable Regions","volume":"86","author":"Bradley","year":"2012","journal-title":"J Virol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00557-08","article-title":"Neutralizing Antibody Blocks Adenovirus Infection by Arresting Microtubule-Dependent Cytoplasmic Transport","volume":"82","author":"Smith","year":"2008","journal-title":"J Virol"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1089\/104303402320138952","article-title":"The Adenovirus Capsid Protein Hexon Contains a Highly Conserved Human CD4 + T-Cell Epitope","volume":"13","author":"Olive","year":"2002","journal-title":"Hum Gene Ther"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.4.1688-1699.2006","article-title":"A Novel Adenovirus Type 6 (Ad6)-Based Hepatitis C Virus Vector That Overcomes Preexisting Anti- Ad5 Immunity and Induces Potent and Broad Cellular Immune Responses in Rhesus Macaques","volume":"80","author":"Capone","year":"2006","journal-title":"J Virol"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107903","article-title":"Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens Following ChAd63- MVA Immunization, Controlled Human Malaria Infection and Natural Exposure","volume":"9","author":"Biswas","year":"2014","journal-title":"PloS One"},{"key":"B218","doi-asserted-by":"publisher","first-page":"261ra153","DOI":"10.1126\/scitranslmed.3009185","article-title":"A Human Vaccine Strategy Based on Chimpanzee Adenoviral and MVA Vectors That Primes, Boosts, and Sustains Functional HCV-Specific T Cell Memory","volume":"6","author":"Swadling","year":"2014","journal-title":"Sci Trans Med"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0646","article-title":"Conserved CTL Epitopes on the Adenovirus Hexon Protein Expand Subgroup Cross-Reactive and Subgroup-Specific CD8+ T Cells","volume":"104","author":"Leen","year":"2004","journal-title":"Blood"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200535786","article-title":"Human CD4+ T Cells Stimulated by Conserved Adenovirus 5 Hexon Peptides Recognize Cells Infected With Different Species of Human Adenovirus","volume":"36","author":"Veltrop-Duits","year":"2006","journal-title":"Eur J Immunol"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.2.1394-1402.1998","article-title":"Nucleotide Sequence, Genome Organization, and Transcription Map of Bovine Adenovirus Type 3","volume":"72","author":"Reddy","year":"1998","journal-title":"J Virol"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00347-3","article-title":"Vaccination With a Single Dose of a Recombinant Porcine Adenovirus Expressing the Classical Swine Fever Virus Gp55 (E2) Gene Protects Pigs Against Classical Swine","volume":"18","author":"Hammond","year":"2000","journal-title":"Vaccine"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1006\/viro.2000.0350","article-title":"Circumvention of Vector-Specific Neutralizing Antibody Response by Alternating Use of Human and non-Human Adenoviruses: Implications in Gene Therapy","volume":"272","author":"Moffatt","year":"2000","journal-title":"Virol"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.01.048","article-title":"Recombinant Ovine Atadenovirus Induces a Strong and Sustained T Cell Response Against the Hepatitis C Virus NS3 Antigen in Mice","volume":"22","author":"W\u00fcest","year":"2004","journal-title":"Vaccine"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1419108","article-title":"Development of Novel Vaccine Vectors: Chimpanzee Adenoviral Vectors","volume":"14","author":"Guo","year":"2018","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02497-06","article-title":"Effect of Preexisting Immunity to Adenovirus Human Serotype 5 Antigens on the Immune Responses of Nonhuman Primates to Vaccine Regimens Based on Human- or Chimpanzee- Derived Adenovirus Vectors","volume":"81","author":"McCoy","year":"2007","journal-title":"J Virol"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101591","article-title":"Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial","volume":"9","author":"Hayton","year":"2014","journal-title":"PloS One"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.83","article-title":"Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants","volume":"24","author":"Afolabi","year":"2016","journal-title":"Mol Ther"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167951","article-title":"Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination With ChAd63 and MVA Encoding ME-TRAP Against Plasmodium Falciparum Infection in Adults in Senegal","volume":"11","author":"Mensah","year":"2016","journal-title":"PloS One"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.20.10780-10789.2003","article-title":"Oral Vaccination of Mice With Adenoviral Vectors is Not Impaired by Preexisting Immunity to the Vaccine Carrier","volume":"77","author":"Xiang","year":"2003","journal-title":"J Virol"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.11.044","article-title":"Intramuscular Rather Than Oral Administration of Replication-Defective Adenoviral Vaccine Vector Induces Specific CD8+ T Cell Responses in the Gut","volume":"25","author":"Lin","year":"2007","journal-title":"Vaccine"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1202288109","article-title":"Long-Lived Epithelial Immunity by Tissue-Resident Memory T (TRM) Cells in the Absence of Persisting Local Antigen Presentation","volume":"109","author":"Mackay","year":"2012","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02864-12","article-title":"Airway Delivery of an Adenovirus-Based Ebola Virus Vaccine Bypasses Existing Immunity to Homologous Adenovirus in Nonhuman Primates","volume":"87","author":"Richardson","year":"2013","journal-title":"J Virol"},{"key":"B234","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12977-017-0336-7","article-title":"Induction of Complex Immune Responses and Strong Protection Against Retrovirus Challenge by Adenovirus-Based Immunization Depends on the Order of Vaccine Delivery","volume":"4","author":"Kaulfub","year":"2017","journal-title":"RetroVirol"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.10.6290","article-title":"Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity","author":"Barouch","year":"2004","journal-title":"J Immunol"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.23.13207-13215.2004","article-title":"Novel Replication-Incompetent Vector Derived From Adenovirus Type 11 (Ad11) for Vaccination and Gene Therapy: Low Seroprevalence and non-Cross-Reactivity With Ad5","volume":"78","author":"Holterman","year":"2004","journal-title":"J Virol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.772659\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T19:41:36Z","timestamp":1675798896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.772659\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":236,"alternative-id":["10.3389\/fonc.2022.772659"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.772659","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]},"article-number":"772659"}}